Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04949828 · ClinicalTrials.gov registry record
Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
A clinical trial of Chronic Pancreatitis, sponsored by AbbVie.
- Completed
- Registry status
- 63
- Enrollment target
- 6
- Study locations
NCT04949828: Completed study of Chronic Pancreatitis, sponsored by AbbVie.
NCT04949828 is a study of Chronic Pancreatitis that has completed, run by AbbVie. The registered enrollment target is 63 participants, below the 687-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04949828, a study of Chronic Pancreatitis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
- 6
- Study locations
Study Summary
Exocrine Pancreatic Insufficiency (EPI) is a condition where pancreatic enzyme quantity or activity is reduced below threshold needed for normal digestion. Symptoms include bloating, flatulence, diarrhea and steatorrhea. This is an observational study assessing for effect of CREON on symptoms of EPI in participants with EPI due to chronic pancreatitis.
Conditions Studied
Interventions
- DRUG CREON
Study Locations (6)
California
- Stanford University School of Med /ID# 229530 - Stanford
Florida
- University of Florida - Archer /ID# 227057 - Gainesville
Maryland
- John Hopkins University /ID# 227061 - Baltimore
New York
- NYU Langone Health /ID# 230818 - New York
Ohio
- The Ohio State University Wexner Medical Center /ID# 227844 - Columbus
Texas
- Baylor College of Medicine - Baylor Medical Center /ID# 227067 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2024-02-29 |
What the finished NCT04949828 record still lists
NCT04949828 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 687-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Chronic Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which CREON is the first listed.
NCT04949828 lists 6 locations in 6 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT04949828 about?
NCT04949828 is a clinical study titled "Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms". Exocrine Pancreatic Insufficiency (EPI) is a condition where pancreatic enzyme quantity or activity is reduced below threshold needed for normal digestion. Symptoms include bloating, flatulence, diarrhea and steatorrhea. This is an observational study assessing for effect of CREON on symptoms of EPI...
What is the current status of trial NCT04949828?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2021-09-16. Estimated completion is 2024-02-29.
What conditions does trial NCT04949828 study?
This clinical trial studies the following conditions: Chronic Pancreatitis.
What interventions are being tested in trial NCT04949828?
The interventions under investigation include: CREON (DRUG).
Who is sponsoring clinical trial NCT04949828?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04949828 being conducted?
This trial has 6 study locations across California, Florida, Maryland, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04949828's enrollment target sits among peer trials
63 23rd of 42 higher than 20 of 42 other Chronic Pancreatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
-
Analysis of Graft Function Following Autologous Islet Transplantation
RECRUITING
-
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
RECRUITING · Early Phase 1
-
Scrambler Therapy in Chronic Pancreatitis
RECRUITING · NA
-
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
RECRUITING
-
Pancreas Registry and High Risk Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI